Guardant Health Inc.(GH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GH Guardant Health Inc.

Post-Mkt 03-16 17:17:29 EDT

87.18

+1.69

+1.98%

盘后87.18

+0.000.00%

16:34 EDT

High88.45	Low86.07	Vol1.39M
Open87.21	D1 Closing85.49	Amplitude2.79%
Mkt Cap11.44B	Tradable Cap10.98B	Total Shares131.17M
T/O120.80M	T/O Rate1.10%	Tradable Shares126.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GH","market":"US","secType":"STK","nameCN":"Guardant Health Inc.","latestPrice":87.18,"timestamp":1773691200000,"preClose":85.49,"halted":0,"volume":1385355,"hourTrading":{"tag":"盘后","latestPrice":87.18,"preClose":87.18,"latestTime":"16:34 EDT","volume":29046,"amount":2532223.192776,"timestamp":1773693274769,"change":0,"changeRate":0,"amplitude":0.013421},"delay":0,"changeRate":0.01976839396420648,"floatShares":126000000,"shares":131170441,"eps":-3.320281,"marketStatus":"Post-Mkt","change":1.69,"latestTime":"03-16 17:17:29 EDT","open":87.21,"high":88.45,"low":86.065,"amount":120801418.25595,"amplitude":0.027898,"askPrice":87.87,"askSize":100,"bidPrice":80.67,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-3.320281,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1773705600000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1538625600000,"exchange":"NASDAQ","adjPreClose":85.49,"preHourTrading":{"tag":"盘前","latestPrice":86.99,"preClose":85.49,"latestTime":"09:25 EDT","volume":19599,"amount":1646853.40458,"timestamp":1773667500065,"change":1.5,"changeRate":0.017546,"amplitude":0.033571},"postHourTrading":{"tag":"盘后","latestPrice":87.18,"preClose":87.18,"latestTime":"16:34 EDT","volume":29046,"amount":2532223.192776,"timestamp":1773693274769,"change":0,"changeRate":0,"amplitude":0.013421},"volumeRatio":0.678903,"impliedVol":0.6404,"impliedVolPercentile":0.5896},"requestUrl":"/m/hq/s/GH","defaultTab":"news","newsList":[{"id":"2619746310","title":"Bitdeer Launches SEALMINER DL1 Air: Achieving 149 J/GH Power Efficiency and 25 GH/s for Scrypt Mining","url":"https://stock-news.laohu8.com/highlight/detail?id=2619746310","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619746310?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:30","pubTimestamp":1773664200,"startTime":"0","endTime":"0","summary":"SINGAPORE, March  16, 2026 (GLOBE NEWSWIRE) -- Bitdeer Technologies Group (NASDAQ: BTDR) (“Bitdeer” or the “Company”), a world-leading technology company for AI and Bitcoin mining infrastructure, toda","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/16/3256284/0/en/Bitdeer-Launches-SEALMINER-DL1-Air-Achieving-149-J-GH-Power-Efficiency-and-25-GH-s-for-Scrypt-Mining.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PW","BK4566","BK4595","BK4196","IE00BN8TJ469.HKD","BK4535","IE00BBT3K403.USD","PEP","IE00BLSP4452.SGD","LU1894683264.USD","LU0320765646.SGD","IE00BLSP4239.USD","BK4023","BK4177","BTDR","GH","BK4550","BK4234","LU1244550494.USD","BK4225","BK4581","LU1929549753.HKD","BK4585","LU1894683348.USD","LU1162221912.USD","BK4588","LU0098860793.USD","LU0234572021.USD","BK4534","LU1244550221.USD","LU1244550577.SGD","BK4084","BK4533","BK4600","IE00B3T34201.USD","BK4551","BK4203","BK4504","LTC"],"gpt_icon":0},{"id":"2619468258","title":"BRIEF-Guardant Health Launches Shield Multi-Cancer Detection (Mcd) Test In Multiple Markets In Asia With Manulife Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2619468258","media":"Reuters","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619468258?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:20","pubTimestamp":1773663619,"startTime":"0","endTime":"0","summary":"BRIEF-Guardant Health Launches Shield Multi-Cancer Detection (Mcd) Test In Multiple Markets In Asia With Manulife PartnershipMarch 16 (Reuters) - Guardant Health Inc GH.O:GUARDANT HEALTH LAUNCHES SHIE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA9BHYZS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4588","BK4535","BK4196","GH","BK4585"],"gpt_icon":0},{"id":"2619468978","title":"Guardant Health Inc - Manulife Customers in Asia to Access Shield Mcd Test Beginning April 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2619468978","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619468978?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:05","pubTimestamp":1773662700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA9BHYZS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GH","BK4585","BK4196","BK4588","BK4551","BK4535"],"gpt_icon":0},{"id":"2619843231","title":"Is Guardant Health’s (GH) Shield Tour Redefining Its Competitive Moat in Cancer Screening?","url":"https://stock-news.laohu8.com/highlight/detail?id=2619843231","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619843231?lang=en_us&edition=fundamental","pubTime":"2026-03-16 14:12","pubTimestamp":1773641534,"startTime":"0","endTime":"0","summary":"Earlier this month, Guardant Health launched Shield Across America, a coast-to-coast mobile tour bringing its FDA-approved Shield blood test for primary colorectal cancer screening directly to more than 100 communities, with a focus on underserved rural areas and screening-eligible adults.\nBy combining this outreach with strong survey support for blood-based screening, updated National Comprehensive Cancer Network guidelines, and broad public payer coverage, Guardant is working to reduce...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/is-guardant-healths-gh-shield-tour-redefining-its-competitiv","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/is-guardant-healths-gh-shield-tour-redefining-its-competitiv","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK4535","BK4585","GH","BK4551","BK4196"],"gpt_icon":0},{"id":"2619438111","title":"Manulife Announces Exclusive Partnership With Guardant Health to Bring the Shield Multi-Cancer Detection Test to Customers Across Asia","url":"https://stock-news.laohu8.com/highlight/detail?id=2619438111","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619438111?lang=en_us&edition=fundamental","pubTime":"2026-03-16 11:00","pubTimestamp":1773630002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA97JSX3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GH","BK4535","BK4196","BK4551","BK4585","BK4588"],"gpt_icon":0},{"id":"2619194223","title":"Guardant Health survey shows 92% support no-copay coverage for colorectal cancer blood tests","url":"https://stock-news.laohu8.com/highlight/detail?id=2619194223","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619194223?lang=en_us&edition=fundamental","pubTime":"2026-03-13 20:09","pubTimestamp":1773403746,"startTime":"0","endTime":"0","summary":"Guardant reported results from a Harris Poll survey of 1,189 U.S. adults aged 45 and older on colorectal cancer screening. The survey found that 92% of screening-eligible adults said blood-based colorectal cancer screening should be covered with no co-pay similar to Medicare Part B and VA Community Care. It also found that 71% said they have felt or would feel anxious before having a colonoscopy, and 77% said they would be less likely to avoid or delay screening if an FDA-approved blood test option were available. Guardant said 85% reported they would be more likely to get a colonoscopy after a positive blood-based screening result, and 54% said stool-based tests “gross them out.” The company also reported a 93% adherence rate in the first 100,000 Shield tests ordered.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL6Mpsrx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4588","BK4535","BK4196","BK4585","GH"],"gpt_icon":0},{"id":"2618614943","title":"Braidwell, Karnal and Kreiter's AI healthcare fund, surged 28% last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2618614943","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618614943?lang=en_us&edition=fundamental","pubTime":"2026-03-11 18:00","pubTimestamp":1773223200,"startTime":"0","endTime":"0","summary":"Braidwell, Karnal and Kreiter's AI healthcare fund, surged 28% last yearBraidwell generated 28% gross return in 2025Braidwell's investments include Guardant Health, Alphatec, and Caris Life SciencesFi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nL6N3ZL1C5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAI","BK4538","BK4585","BK4588","LU1585245621.USD","LU1778281490.HKD","ATEC","BK4196","BK4602","BK4082","LU0321505439.SGD","BK4104","BK4575","GH","LU1674673428.USD","IBM","LU0868494617.USD","LU1559883803.SGD","BK4551","BK4134","BK4535","BK4533","BK4139","LU0566484027.USD","BK4543","LU1883839398.USD","LU1894683348.USD","LU1880398554.USD","LU0321505868.SGD","BK4612","BK4534","BK4579","LU1674673691.USD","LU1880398471.USD","LU1430594728.SGD","LU1894683264.USD"],"gpt_icon":0},{"id":"2618934984","title":"GH Research price target raised to $34 from $29 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2618934984","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618934984?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:01","pubTimestamp":1773140494,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Eddie Hickman raised the firm’s price target on GH Research (GHRS) to $34 from $29 and keeps a Buy rating on the shares after th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gh-research-price-target-raised-to-34-from-29-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gh-research-price-target-raised-to-34-from-29-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GH"],"gpt_icon":0},{"id":"2617204659","title":"Analysts Offer Insights on Healthcare Companies: GH Research (GHRS) and Sionna Therapeutics, Inc. (SION)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617204659","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617204659?lang=en_us&edition=fundamental","pubTime":"2026-03-07 09:50","pubTimestamp":1772848211,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on GH Research (GHRS – Research Report) and Sionna Ther...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-gh-research-ghrs-and-sionna-therapeutics-inc-sion-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-gh-research-ghrs-and-sionna-therapeutics-inc-sion-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4551","BK4137","BK4539","LU0128526141.USD","BK4585","GH","LU0029874061.USD","BK4581","BK4139","BK4007","SION","XBI","HCSG","BK4588","GHRS","BK4196","BK4535","XLV","LABU"],"gpt_icon":0},{"id":"2617687951","title":"GH Research Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2617687951","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617687951?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:19","pubTimestamp":1772799540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GHRS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 06, 2026 07:19 ET (12:19 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"gpt_icon":0},{"id":"2617097682","title":"Stifel Nicolaus Sticks to Their Buy Rating for GH Research (GHRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617097682","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617097682?lang=en_us&edition=fundamental","pubTime":"2026-03-06 19:58","pubTimestamp":1772798311,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst reiterated a Buy rating on GH Research today and set a price target of $32.00. In a report released today, Citizens JMP als...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-their-buy-rating-for-gh-research-ghrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-their-buy-rating-for-gh-research-ghrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","GH","GHRS"],"gpt_icon":0},{"id":"2617682064","title":"Canaccord Genuity Reaffirms Their Buy Rating on GH Research (GHRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617682064","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617682064?lang=en_us&edition=fundamental","pubTime":"2026-03-06 19:58","pubTimestamp":1772798290,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst Sumant Kulkarni reiterated a Buy rating on GH Research today and set a price target of $39.00. Kulkarni covers the Health...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-reaffirms-their-buy-rating-on-gh-research-ghrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-reaffirms-their-buy-rating-on-gh-research-ghrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GHRS","GH"],"gpt_icon":0},{"id":"2617740775","title":"Guardant Health CIO Kumud Kalia Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2617740775","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617740775?lang=en_us&edition=fundamental","pubTime":"2026-03-06 06:44","pubTimestamp":1772750696,"startTime":"0","endTime":"0","summary":"Kumud Kalia, Chief Information Officer of Guardant Health Inc., reported a disposal of the company’s common shares. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL1ND1Nk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health CIO Kumud Kalia Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4551","BK4196","BK4535","GH"],"gpt_icon":0},{"id":"2617544118","title":"GH Research's 2025 Net Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2617544118","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617544118?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:26","pubTimestamp":1772713613,"startTime":"0","endTime":"0","summary":"GH Research (GHRS) reported a 2025 net loss Thursday of $0.79 per diluted share, widening from a loss of $0.75 a year earlier.Four analysts polled by FactSet expected a loss of $0.89.As of Dec. 31, the company said it had $280.7 million in cash and or cash equivalents on hand.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4535","BK4588","BK4007","GH","BK4196","BK4585","BK4551","GHRS","BK4539"],"gpt_icon":0},{"id":"2617544845","title":"GH Research Q4 EPS $(0.23) Beats $(0.28) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2617544845","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617544845?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:14","pubTimestamp":1772712896,"startTime":"0","endTime":"0","summary":"GH Research (NASDAQ:GHRS) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.28) by 17.56 percent. This is a 35.29 percent decrease over losses of $(0.17) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51062331/gh-research-q4-eps-0-23-beats-0-28-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"gpt_icon":0},{"id":"2617541137","title":"Press Release: GH Research Reports Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2617541137","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617541137?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:00","pubTimestamp":1772712000,"startTime":"0","endTime":"0","summary":"-- Completed Phase 2b trial of GH001 in TRD and presented the full dataset. -- GH001 cleared by FDA for U.S. clinical investigation, enabling U.S.DUBLIN, Ireland, March 05, 2026  -- GH Research PLC , a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the year ended December 31, 2025, and provided a business update.\"Our Phase 2b results reinforce our conviction that GH001 has the potential to be a practice-changing therapy for patients with TRD,\" said Dr. Velichka Valcheva, Chief Executive Officer. \"We look forward to aligning with the FDA on our global Phase 3 program, replicating phase 2b design, and advancing this innovative program with initiation targeted for 2026.\". Cash, cash equivalents and marketable securities were $280.7 million as of December 31, 2025, compared to cash, cash equivalents, other financial assets and mark","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH","BK4535","BK4196","BK4551","BK4585","GHRS","BK4007","BK4588","BK4539"],"gpt_icon":0},{"id":"2616373416","title":"Analysts Offer Insights on Healthcare Companies: Guardant Health (GH) and 908 Devices (MASS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616373416","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616373416?lang=en_us&edition=fundamental","pubTime":"2026-03-04 02:30","pubTimestamp":1772562608,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Guardant Health (GH – Research Report) and 908 Devic...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-guardant-health-gh-and-908-devices-mass-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-guardant-health-gh-and-908-devices-mass-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4535","HCSG","LU0029874061.USD","XLV","BK4581","MASS","LU0128526141.USD","LABU","XBI","GH","BK4585","BK4551","BK4588","BK4157","BK4196"],"gpt_icon":0},{"id":"2616342964","title":"Patrick Dempsey Partners With Guardant Health to Promote Shield Colorectal Cancer Screening Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2616342964","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616342964?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:04","pubTimestamp":1772539447,"startTime":"0","endTime":"0","summary":"Guardant Health Inc. has partnered with actor and cancer advocate Patrick Dempsey to raise awareness of colorectal cancer screening and promote its FDA-approved Shield blood test. The collaboration will spotlight Dempsey’s personal screening experience and encourage eligible adults aged 45 and older at average risk to discuss screening options with their healthcare providers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief on March 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL755TXv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH","BK4196","BK4535","BK4588","BK4585","BK4551"],"gpt_icon":0},{"id":"2616358672","title":"GH Research Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2616358672","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616358672?lang=en_us&edition=fundamental","pubTime":"2026-03-02 22:03","pubTimestamp":1772460180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GHRS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 02, 2026 09:03 ET (14:03 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"gpt_icon":0},{"id":"2616390233","title":"H.C. Wainwright Keeps Their Buy Rating on GH Research (GHRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616390233","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616390233?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:55","pubTimestamp":1772452532,"startTime":"0","endTime":"0","summary":"In a report released today, Patrick Trucchio from H.C. Wainwright maintained a Buy rating on GH Research, with a price target of $70.00. Trucchio c...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-gh-research-ghrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-gh-research-ghrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GH","GHRS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.guardanthealth.com","stockEarnings":[{"period":"1week","weight":-0.0626},{"period":"1month","weight":-0.2053},{"period":"3month","weight":-0.1624},{"period":"6month","weight":0.5573},{"period":"1year","weight":1.1036},{"period":"ytd","weight":-0.163}],"compareEarnings":[{"period":"1week","weight":-0.015},{"period":"1month","weight":-0.0429},{"period":"3month","weight":-0.0286},{"period":"6month","weight":0.0074},{"period":"1year","weight":0.2011},{"period":"ytd","weight":-0.0288}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.071093},{"month":2,"riseRate":0.25,"avgChangeRate":0.034152},{"month":3,"riseRate":0.5,"avgChangeRate":-0.031967},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.017651},{"month":5,"riseRate":0.571429,"avgChangeRate":0.065461},{"month":6,"riseRate":0.714286,"avgChangeRate":0.081894},{"month":7,"riseRate":0.714286,"avgChangeRate":0.051469},{"month":8,"riseRate":0.571429,"avgChangeRate":0.08346},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.065825},{"month":10,"riseRate":0.285714,"avgChangeRate":0.030366},{"month":11,"riseRate":0.75,"avgChangeRate":0.130427},{"month":12,"riseRate":0.5,"avgChangeRate":-0.066498}],"exchange":"NASDAQ","name":"Guardant Health Inc.","nameEN":"Guardant Health Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Guardant Health Inc.(GH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Guardant Health Inc.(GH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Guardant Health Inc.,GH,Guardant Health Inc.股票,Guardant Health Inc.股票老虎,Guardant Health Inc.股票老虎国际,Guardant Health Inc.行情,Guardant Health Inc.股票行情,Guardant Health Inc.股价,Guardant Health Inc.股市,Guardant Health Inc.股票价格,Guardant Health Inc.股票交易,Guardant Health Inc.股票购买,Guardant Health Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Guardant Health Inc.(GH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Guardant Health Inc.(GH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}